Navigation Links
FDA Panel Mulls Safety of Asthma Meds
Date:12/11/2008

Long-acting beta agonists may cause asthma problems and death, agency officials warn

THURSDAY, Dec. 11 (HealthDay News) -- The safety of four asthma medications will be weighed by a U.S. Food and Drug Administration expert panel as two days of hearings end Thursday.

The controversy over these drugs has been going on for several years, with two FDA officials recently calling for banning the use of these drugs for anyone under 17.

One expert thinks the problem is not with the drugs, but with their misuse.

"This is an over-interpretation of the risk without adequate consideration of benefit," said Dr. Miles Weinberger, a professor of pediatrics at the University of Iowa. "However, there has been irresponsible marketing of the products, salmeterol and formoterol, and irresponsible prescribing by many physicians."

"Since most patients with chronic asthma can be controlled with inhaled steroids alone, using these more expensive combination formulations as first line is inappropriate but strongly encouraged by marketing practices" of drug makers, Weinberger said.

The products under review are Advair (salmeterol, fluticasone), Foradil (formoterol), Serevent (salmeterol), and Symbicort (formoterol, budesonide). Advair and Symbicort are combination products containing both a long-acting beta agonist and an inhaled corticosteroid. These drugs relax airway muscles, letting asthma patients breathe more easily.

In the panel's first day of hearings Wednesday, FDA officials themselves were split over the risks of the drugs.

One official told the panel members that more than 14,000 people may have died since 1994 after taking the drugs, while another suggested that an even greater number might have died without them, according to The New York Times.

Last week, two FDA officials, who work in the agency's safety division, posted an assessment on the agency Web site, sayin
'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved  

0

GOOD

Page: 1 2 3

Related medicine news :

1. Abaxis Point-of-Care Test Panels Gain FDA CLIA-Waived Status
2. Bradmer to participate in panel presentation at RBC Capital Markets Healthcare Conference
3. Instrumentation Laboratory Announces ILeader Panel of Experts as Part of 50th Anniversary Program
4. OneMedPlace announces panels for "OneMedForum 2009: Disrupters and Drivers in Eight Areas of Medical Technology" -- CEOs and investors to meet in unique format of focused sessions
5. Genaera to Participate in Obesity Panel at RBC Capital Markets Healthcare Conference
6. DRE Veterinary Introduces Dynamic Flat Panel Monitor
7. Transcept Pharmaceuticals to Participate on Drug Delivery Investor Panel
8. Panel Demands FDA Action to Address Dramatic Increases in Skin Cancer in U.S.
9. Epocrates Offers International Market Research Panel
10. Wrinkle Fillers Need Better Label Warnings: FDA Panel
11. Gulf War research panel finds 1 in 4 veterans suffers from illness caused by toxic exposure
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Panel Mulls Safety of Asthma Meds
(Date:6/19/2013)... Pa. (June 19, 2013) The results of three ... of Neurosurgery , official journal of the ... published by Lippincott Williams & Wilkins , a ... study indicates that continuous "machine learning" using artificial neural ... in patients with advanced brain cancers. Another study in ...
(Date:6/19/2013)... is available in Spanish . ... neglected diseases, it goes by the name of the 10/90 ... devoted to conditions that accounted for 90 per cent of ... that the Drugs for Neglected Diseases initiative (DNDi) came into ... organization has been granted the BBVA Foundation Frontiers of Knowledge ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 ... of neurologists, neurosurgeons, psychiatrists and urologists with specialists ... The team works with patients and their family ... overall quality of life. Patients also have the ... trials and research. , “Movement disorders can be ...
(Date:6/19/2013)... June 19, 2013 North Carolina-based ... organizational changes to advance development of its technologies. ... “To support the advanced development of our product ... to the Company’s management structure and engaged industry ... Company announced that Michael Galiger will serve as ...
(Date:6/19/2013)... DiscountFurnaceFilter.com, the number one solution for homeowner’s indoor air ... kit at an exceptional price. The 5-2-1 Compressor Saver (also ... unit during start up, saving wear and tear on the ... out. , The 5-2-1 Compressor Saver works by ... power to start and drastically reduces the rush of heat ...
Breaking Medicine News(10 mins):Health News:Neurosurgery publishes findings of 3 important studies in June issue 2Health News:Neurosurgery publishes findings of 3 important studies in June issue 3Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 2Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 3Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 4Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 5Health News:Abington Memorial Hospital’s Neurosciences Institute Opens Movement Disorders Center 2Health News:Entegrion Announces Organizational Changes to Support Advanced Product Development 2Health News:Entegrion Announces Organizational Changes to Support Advanced Product Development 3
... how the risk of death and heart attack can be ... that doubling the usual dose of an anti-clotting drug before ... in which a balloon-tipped catheter is threaded into an artery. ... and unblock the vessel. A small synthetic tube - stent ...
... has been found out that there is no association between ... -- and breast cancer. More than 43,000 women were studied ... had their average daily intake of acrylamide monitored. No evidence ... whose intake was higher was documented. Acrylamide was first discovered ...
... In the 83rd General Session of the International Association ... have presented the results of a study// that says ... bad breath. ,Oral bad odor or so called ... compounds like hydrogen sulfide. The study revealed that volunteers ...
... A new study has found out that depression has to ... anti-depressants // used to treat the same. The study was ... ,At first glance, results showed both the newer and older ... attack within the first month of being prescribed.The older class ...
... drug tezosentan did not improve worsening heart failure or prevent ... hopes. The above fact was found out in the largest ... was conducted to evaluate if something more could be done ... hospital discharge and prevent them from coming back. ,More ...
... help in controlling obesity. A new study coming up in ... that dietary calcium present in the yogurt has got anti-obesity ... and decrease in lipogenesis. ,The study took ... put on balanced deficit diets and the other was put ...
Cached Medicine News:
(Date:6/19/2013)... DIEGO , June 19, 2013   Nektar Therapeutics ... results from a human abuse liability (HAL) study for ... rate of entry into the brain.  This slow rate of ... to the abuse of and addiction to current opioid analgesics. ... NKTR-181 was rated similar to placebo in "drug liking" ...
(Date:6/19/2013)... -- Today leading web researchers Change Sciences Group ( ... sites for usability, engagement, and conversion. The rankings are ... compares how people experience sites with competitors and with ... top three performers are easier to use, more engaging ... have usability problems, lack aspects of design that compel ...
(Date:6/19/2013)... , June 19, 2013 Today ... solutions, introduced the next-generation of its Employer ... allows health plans to provide their employer groups ... health factors, medical and prescription drug claims, network ... (Logo: http://photos.prnewswire.com/prnh/20100621/SF23660LOGO ) "Employer ...
Breaking Medicine Technology:Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 2Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 4Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 5Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 6Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 7Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 8Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 9Sunovion tops new Change Sciences User Experience Rankings for Pharmaceutical Industry while McNeil-PPC ranks worst overall 2MedeAnalytics Introduces Next-Generation Employer Group and Individual Business Analytics Solution 2
... In 2009, more than 30 million people delayed seeking ... needed care due to the rising costs of healthcare in ... and cannot afford their prescriptions, medical treatment or even a ... dietary supplement brand with more than 10 years in the ...
... Jan. 24, 2011 NxStage Medical, Inc. (Nasdaq: ... products, today announced the addition of Nancy J. Ham ... of Jonathan T. Silverstein. Mr. Silverstein, General ... the Company,s 2008 financing, in which OrbiMed was the ...
Cached Medicine Technology:Codeco® Nutrilife Brings Hope to Hispanics Through Alternative Medicine 2NxStage® Appoints Nancy J. Ham to Its Board of Directors and Announces Resignation of Board Member Jonathan T. Silverstein 2
... versatility, and environmental safety are ... LE-80 K Ultracentrifuge from Beckman ... Optima centrifugation technology, the LE-80 ... effectively provide advanced capability for ...
... With the ability to provide a simple, ... in lipemic samples), the Airfuge CLS delivers ... can be cleaned in 10 minutes, eliminating ... tabletop centrifuge: Reaches top speed in as ...
The Dimension RxL Max is an integrated chemistry system and is the most powerful and technologically advanced Dimension analyze with new standard for excellence in clinical diagnostics. Simply put, t...
... Microvolume technology , The ADVIA ... (as low as 2 L/test), reagent consumption ... consumption (25 L/hour) - thus maximizing management ... rapid, 3-second cycle and system throughput of ...
Medicine Products: